Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28869660 | 0.85 | HDAC1 (0.53) | MAPK14MEN1KMT2ACES2CES1 | |
| SCHEMBL11636186 | 0.85 | GAA (0.48) | GAAMEN1KMT2ACES2CES1 | |
| SCHEMBL20447555 | 0.83 | ALDH1A1 (0.46) | MAPK14MEN1KMT2ACES2CES1 | |
| SCHEMBL909599 | 0.82 | CES2 (0.61) | GAAKMT2ACES2CES1HDAC1 | |
| Hydrochloric Acid SCHEMBL29775858 | 0.81 | CES2 (0.59) | GAAKMT2ACES2CES1HDAC1 | |
| SCHEMBL1774955 | 0.81 | GAA (0.48) | GAACES2CES1KDM4EHPGD | |
| SCHEMBL24571696 | 0.80 | ALDH1A1 (0.47) | GAAMEN1KMT2AHPGDNPC1 | |
| SCHEMBL30441657 | 0.80 | ALDH1A1 (0.47) | GAAMEN1KMT2AHPGDNPC1 | |
| SCHEMBL25376547 | 0.80 | SLC6A9 (0.46) | MAPK14MEN1KMT2ACES2CES1 | |
| SCHEMBL4599072 | 0.80 | POLB (0.50) | MEN1KMT2ACES2CES1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| WO-2022000443-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-01-06 | — | — | WO | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2298747-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
| US-4107311-A | ANTI-FERTILITY AGENTS, ABORTIFACIENTS | SANDOZ, INC. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4083997-A | ANTIDEPRESSANTS | SANDOZ, INC. (US) | 1978-04-11 | — | — | US | disclosed |
| US-3994961-A | ANTIDEPRESSANTS | SANDOZ, INC. (US) | 1976-11-30 | — | — | US | disclosed |
| US-3956391-A | Amino substituted tetrahydropleiadenes | SANDOZ, INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | GAA 1904/4885MAPK14 583/4885MEN1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.